Zepbound
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Zepbound?
Tirzepatide sold as a weekly injection for weight management, approved 2023, and since December 2024 also for sleep apnea (moderate or severe) when the patient has obesity.
It is a dual GLP-1/GIP agonist, and the trial number people quote is about 21% body weight reduction at 15 mg in SURMOUNT-1. It is the brand compounded sellers most often position against.
Read more:
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Zepbound comes up on this site
On GLP Watchdog, Zepbound comes up in 119 research articles, 136 seller reviews, 7 FDA warning letters and 4 tools. Browse the FDA warning letters.
Research that discusses it
- Does Delaware Medicaid Cover Wegovy and Zepbound? Yes, With a Health-Condition Rule
- Does Medicaid Cover Zepbound? The Federal Rule and the Sleep Apnea Indication
- Does Mississippi Medicaid Cover Wegovy and Zepbound? Coverage, Criteria and Who Stays On
- How Long Can Zepbound, Wegovy and Ozempic Be Out of the Fridge?
- How Long Do Zepbound, Wegovy and Other GLP-1s Stay in Your System?
- Phentermine vs Ozempic, Wegovy and Zepbound: Is Phentermine a GLP-1?
- All 119 articles are on the research page
Tools that use it
Seller reviews that mention it
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers